Dysfunction of the Prefrontal Cortex in Addiction

Prefrontal Cortex Dysfunction and the iRISA Model

• Core Concept: Drug addiction is conceptualized under the impaired response inhibition and salience attribution (iRISA) model, wherein prefrontal cortex (PFC) dysfunction drives excessive salience attribution to drugs/cues, reduced sensitivity to non-drug reinforcers, and compromised self-control.
• Relapsing Cycle: Addiction encompasses four core clinical stages: intoxication, bingeing, withdrawal, and craving.
• Shift in Focus: Beyond subcortical mesolimbic dopamine reward circuits, the PFC is critical due to its dual role in regulating limbic reward regions and executing higher-order cognitive functions.

Prefrontal Subregions and Functional Specialization

• Dorsolateral Prefrontal Cortex (DLPFC) & Dorsal Anterior Cingulate Cortex (dACC): Primary centers for "cold" executive processes, including top-down inhibitory control, working memory, attention allocation, conflict detection/resolution, and action planning.
• Medial Orbitofrontal Cortex (mOFC), Ventromedial PFC (vmPFC), & Rostroventral ACC: Specialized for "hot" emotional processes, including emotion regulation, conditioning, assigning incentive salience, and processing drug-related craving.
• Ventrolateral PFC (vlPFC) & Lateral OFC: Mediate automatic response tendencies, response inhibition, and valuation of outcomes.
• Disease Awareness & Insight: Dysfunctions in the rostral/dorsal ACC, mPFC, OFC, and vlPFC lead to a dissociation between self-report and actual behavior, contributing to impaired interoceptive awareness and "denial" of illness severity.

Neuropsychological Dynamics in Addiction

• Drug and Cue Reactivity: Direct drug intake and conditioned drug cues elicit widespread hyperactivation across PFC networks (mOFC, vmPFC, ACC, DLPFC), which correlates with subjective craving and severity of drug use.
• Blunted Response to Non-Drug Rewards: PFC sensitivity (specifically in the OFC, DLPFC, and ACC) to non-drug reinforcers, such as monetary gains, is markedly blunted, resulting in a flattened reinforcer gradient and preference for immediate over delayed rewards.
• Inhibitory Control Deficits: Performance on Go/No-Go, Stop Signal Reaction Time (SSRT), and Stroop tasks reveals persistent dACC and DLPFC hypoactivity during response inhibition and error processing.
• Cognitive Competition Model: In a healthy state, dorsal PFC top-down control inhibits automatic drug responses ("Stop!"). During craving and withdrawal, drug-related functions eclipse non-drug functions ("Stop?"). During intoxication/bingeing, ventral "hot" emotional regions suppress higher-order control, yielding compulsive drug seeking ("Go!").

Neurochemistry, Structural Abnormalities, and Interventions

• Neurotransmitter Alterations: Addiction is characterized by blunted striatal dopamine $D_2$ receptor availability, attenuated striatal dopamine release, elevated mu opiate receptor binding potential in the DLPFC and ACC, and reduced serotonin transporter availability.
• Structural Changes: Widespread grey matter reductions (up to $20\%$ loss) occur in the DLPFC, ACC, and OFC across addictive disorders, persisting through extended abstinence.
• Vulnerability Factors: Pre-morbid risks include genetic polymorphisms (e.g., $DRD4$, $DRD2$, $CB1$, $FAAH$, $MAOA$), family history of substance abuse, and prenatal drug exposure.
• Therapeutic Normalization: Acute administration of dopamine-enhancing agents, such as oral methylphenidate (MPH), normalizes dACC and rvACC activity and improves response inhibition during cognitive and emotional tasks.